# MSK Pavilion

#### **ULURP Number:**

C 240237 ZMM (LU 0132-2024)

N 240238 ZRM (LU 0133-2024)

C 240235 ZSM (LU 0134-2024)

M 240240 LDM (LU 0135-2024)

C 240236 GFM (LU 0136-2024)

NYC Council Subcommittee on Zoning and Franchises September 10, 2024




If you are a member of the public who wishes to testify, please register on the City Council Website at council.nyc.gov. Please visit the City Council Website to watch livestreams of all City Council Meetings and find recordings of previously held meetings.

## Why Do We Need the Pavilion?

# Cancer rates will increase 50% by 2050

- 1 in 3 people will have cancer at some point in their lifetime.
- New York City currently sees 40,000 new cases per year.
  - 47,000+ cases projected by 2030; 60,000 by 2050.
- Two groups of particular concern:
  - Older New Yorkers.
  - Younger New Yorkers with rising rates of prostate, colon, and breast cancer.



90-115%

MSK's bed occupancy rate (2023)

## What is the Pavilion?

#### The Pavilion will help us:

- Meet the anticipated increased demand for care
- Accommodate modern and future technology


#### The facility will feature:


- 28 new operating rooms, 206 inpatient beds (40 ICU beds)
- New advanced technologies and operating capabilities
- Single rooms for immunocompromised patients
- Connection to Memorial Hospital via a patient bridge to ensure the highest quality of care and safety for our patients
- Location next door to our research labs and core facilities



#### **Operating Rooms**

#### Clearances & Dimensions






600 SF Minimum Clear Floor Area

#### **Critical Patient Rooms**

Clearances & Dimensions




Medical/Surgical Patient Floor



Surgical Suite Floor



Program Stacking Diagram (with MEP Ceiling Area)



**PATIENT** SURGERY **CLINICAL SUPPORT** 

LOBBY

**MECHANICAL** 

## **Pavilion**

**Urban Context** 







## **MSK Pavilion**

#### **APPLICANT**

Memorial Sloan Kettering Cancer Center

#### **REQUESTED ACTIONS**

- Zoning Map Amendment to rezone midblock of project area from R8 to R9
- **Zoning Text Amendment** to ZR 79-43 to enable lot coverage and signage modifications by special permit.
- ZR 79-43 Special Permit to modify height, setback, lot coverage and signage
- **ZR 79-21 Authorizations** to enable the development without regard for height and setback regulations, rear yard regulations and distribute floor area within a LSCFD without regard for zoning lot lines and streets
- Modification to the 2001 LSCFD site plan
- Cancellation of the 2001 LSCFD Restrictive Declaration
- ZR 26-15 Curb Cut Certification
- Revocable Consent for a pedestrian bridge over East 67th Street



## **Environmental Review**

- A Notice of Completion (NOC) on the Final Environmental Impact Statement (FEIS) was issued by DCP on July 26, 2024
- FEIS identified significant adverse impacts with respect to:
  - Shadows
  - Construction (Transportation Traffic)
  - Construction (Noise)
- No other significant adverse impacts were identified.
- A Restrictive Declaration has been executed and will be recorded upon ULURP approval to initiate all identified Mitigation Measures in concert with the Community and relevant City Agencies.

#### **Community Board 8 Engagement**

Resolution passed 24-11-1 recognizing the need for the project along with community recommendations for the project.

#### Manhattan Borough President Recommendation

Approval with Condition

## **City Planning Commission**


Unanimous Approval – Excerpt:

"...With a projected rise in cancer rates [MSK] can no longer sufficiently meet its inpatient care needs amid increasing current and future demands."

## **APPENDIX**

Program Stacking Diagram (Percentages)





Annual Report to the Nation on the Status of Cancer, 1973-1999, Featuring Implications of Age and Aging on U.S. Cancer Burden

Projected Cancer Cases in USA 2020: 1.8 Million




FIGURE 5. Projected number of cancer cases for 2000 through 2050 based on projected census population estimates and age-specific cancer incidence rates,

# THANK YOU

